API | pamrevlumab

pamrevlumab Report issue

Biologics mAb Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Pamrevlumab is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. It binds to the connective tissue growth factor (CTGF) protein. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
pamrevlumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Connective tissue growth factor (Homo sapiens) ^UniProt
- Connective tissue growth factor (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

fg3019 | fg 3019 | fg-3019 | pamrevlumab

Organizations (46)

Research & Development (46)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)

COVID-19 (Phase 2/Phase 3)

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 2 (Phase 2)

Diabetic Nephropathies (Phase 2)

Glomerulosclerosis, Focal Segmental (Phase 1)

Hepatitis B (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 3)

Muscular Dystrophy, Duchenne (Phase 3)

Pancreatic Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 19
# of Trial Organizations: 46

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue